These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 22768790)

  • 1. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.
    Honarvar H; Strand J; Perols A; Orlova A; Selvaraju RK; Eriksson Karlström A; Tolmachev V
    Mol Imaging; 2014; 13():. PubMed ID: 25249017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
    Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
    Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
    Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
    Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
    Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
    Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
    Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
    PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
    Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
    Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
    Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
    Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
    Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
    Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
    Westerlund K; Honarvar H; Tolmachev V; Eriksson Karlström A
    Bioconjug Chem; 2015 Aug; 26(8):1724-36. PubMed ID: 26086597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.